Kari Flynn
Acute Care · Paoli, PANPI 1235777863
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 236 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AstraZeneca at 27.9% of the total. Among acute care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$658
- Johnson & Johnson$376
- Boehringer Ingelheim$312
- Amgen$309
- Mylan Specialty L.p.$305
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,112100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $1,705 |
| GSK | 39 | $658 |
| Johnson & Johnson | 12 | $376 |
| Boehringer Ingelheim | 14 | $312 |
| Amgen | 6 | $309 |
| Mylan Specialty L.p. | 15 | $305 |
| Philips North America LLC | 9 | $281 |
| Regeneron Healthcare Solutions, Inc. | 9 | $273 |
| Insmed, Inc. | 8 | $257 |
| Viatris Specialty LLC | 7 | $238 |
| Sanofi | 7 | $185 |
| E.r. Squibb & Sons, L.L.C. | 2 | $166 |
| Mallinckrodt Hospital Products Inc. | 4 | $165 |
| Verona Pharma, Inc. | 5 | $113 |
| Electromed, Inc. | 5 | $110 |
| United Therapeutics Corporation | 4 | $93 |
| Merck | 1 | $81 |
| Baxter Healthcare | 2 | $67 |
| Inogen, Inc. | 2 | $55 |
| Harmony Biosciences LLC | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Genentech USA, Inc. | 2 | $47 |
| Pfizer | 2 | $45 |
| Novartis | 2 | $41 |
| ANI Pharmaceuticals, Inc. | 1 | $34 |
| Lilly USA, LLC | 1 | $32 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Pulmonx Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,112 in reported general payments places this provider in the 95th percentile of 872 acute care providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 228 | $193,945 |
| Dupixent PenDupilumab | 23 | $85,590 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 105 | $73,851 |
| Spiriva RespimatTiotropium Bromide | 63 | $38,618 |
| EliquisApixaban | 42 | $36,944 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $35,974 |
| Breo ElliptaFluticasone/Vilanterol | 70 | $31,310 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $14,051 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $10,567 |
| Pirfenidone | 13 | $9,944 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 67 | $9,360 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $8,473 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $6,237 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 43 | $4,747 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 159 | $4,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $658 | $269,702370 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,705 | $94,139177 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $312 | $49,18678 claims |
| PfizerEliquis | $45 | $36,94442 claims |
| MerckDulera | $81 | $3,29811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 872 acute care providers in Pennsylvania.
Other acute care in Paoli
- Lynn WolffPaoli$3K
- Kristi MontrellaAltoona$111K
- Kathryn GreenPhiladelphia$92K
- Caroline PratzPhiladelphia$77K
- Donna KinzlerPittsburgh$25K
- Lisa JohnsonPottstown$25K
- Kathryn McParlaneMoon Township$21K
- Rebecca MarcantuonoPhiladelphia$17K
- Stephanie TothPhiladelphia$17K
- Kevin HaganAbington$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.